Learning Objectives: -Analyze key safety and efficacy data from pivotal clinical trials assessing both current and emerging therapies designed for patients with MM -Determine the impact of disease- and patient-specific factors, along with prior treatment history, on therapy selection for patients with MM -Formulate proactive approaches to monitor, prevent, and mitigate treatment-related toxicities in both frontline and relapsed/refractory MM settings
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://www.gotoper.com/courses/new-horizons-in-multiple-myeloma-treatment-selection-and-sequencing-from-newly-diagnosed-to-relapsedrefractory-disease-3hsd
- Start Date: 2024-09-24 05:00:00
- End Date: 2024-09-24 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Janssen (Any division) - Amount: 50000.0 - Is Kind Support: False Source: Sanofi-Genzyme - Amount: 30000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology
Subscribe
Login
0 Comments
Oldest